Barclays on Wednesday upgraded Evonik (ETR:EVK) to Overweight from Equal Weight and nudged up its target price to €17 from €16. The bank said renewed tightness in the methionine market, driven by recent supply shocks in Asia, has turned what was previously a normalization risk into a supportive factor for prices and margins.
Barclays noted that its new €17 target implies roughly 15% upside from Tuesday's close of €14.79. The bank's reassessment of methionine dynamics reflects disruptions linked to the Middle East conflict that have constrained feedstock availability and complicated logistics through the Strait of Hormuz.
Those constraints were brought into sharper relief after a major raw material supplier declared force majeure, a move that led Evonik to announce its own force majeure status when output at part of the supplier's Singapore methionine facility was curtailed. Barclays emphasized the supplier's force majeure pertains to only a small portion of the plant, so immediate volume losses are likely to be modest. Still, the same supply shock has rippled through Asia's petrochemical chain, increasing the odds that Chinese producers will also face difficulties in securing inputs and managing exports - a development that should temper aggressive price competition in the region.
The regional footprint of methionine capacity matters to this assessment. Asia represents 64% of global methionine capacity, split between China at 35% and the rest of Asia at 29%. Outside Asia, Evonik commands 44% of capacity, making it the largest non-Asian producer, ahead of peers Novus at 34% and Adisseo at 19%. Barclays argued that if Asian availability tightens further, buyers in Europe and the United States are likely to source more volume from non-Asian producers, shifting flows toward Evonik and providing a floor under prices.
Price moves are already evident. Barclays said methionine spot prices have risen materially in China and Europe. When current spot pricing is marked to the books, the bank calculates a roughly €315 million net pricing benefit, compared with a negative €140 million impact based on February pricing. That difference translates to an approximate €450 million swing to EBITDA in March, according to Barclays.
Alongside that pricing revision, Barclays adjusted its net pricing impact assumption from negative €105 million to zero, which lifted its 2026 EBITDA forecast for Evonik to €1.89 billion. That figure sits about 3% above Bloomberg consensus and falls within Evonik's own guidance range of €1.7 billion to €2 billion.
Barclays also highlighted operational factors that improve Evonik's earnings resilience. The bank pointed to Evonik's energy hedging - roughly 80% of the company's energy needs are covered by pre-arranged contracts. Barclays contrasted that with materially lower hedge levels at many peers, arguing Evonik is better insulated from volatile energy costs, frequent price resets and margin erosion that can afflict competitors across the sector.
On strategic matters, Barclays flagged potential upside tied to portfolio moves. At its recent capital markets day Evonik said it would pause M&A until 2027 and concentrate on deleveraging and completing planned disposals, including Syneqt and Oxeno. Barclays drew a valuation parallel to recent transactions in the chemical infrastructure services arena - specifically Macquarie's purchase of 49% of Diamond Infra from Dow at 9 times EV/EBITDA - and suggested Syneqt, which generates roughly €200 million in EBITDA, could command a multiple above Evonik's current group multiple.
Valuation-wise, Barclays applies a 12 times multiple to Evonik's 2027 EPS, consistent with the bank's five-year average, and arrived at the €17 price target.
What this means
- Barclays' upgrade reflects a shift from concern about methionine price normalization to recognition of a supply-driven pricing tailwind.
- Non-Asian production, led by Evonik, stands to capture incremental volume if Asian supply remains constrained.
- Energy hedges provide Evonik greater earnings stability relative to many peers during a period of commodity and logistics volatility.
Context and caveats
The positive re-rating rests on a set of observed supply disruptions and their presumed persistence across Asian petrochemicals. Barclays notes the supplier rupture in Singapore affects only part of output, so near-term volume constraints may be limited. That said, the same chain-level pressure that has strained inputs and export logistics in Asia underpins the bank's argument that Chinese competitors may struggle, which would blunt pricing competition and support firmer global prices.
Barclays' revised estimates feed through to an upgraded earnings profile and valuation, but those outcomes remain sensitive to how long supply disruptions persist and how the broader energy cost environment evolves.
Reporting follows Barclays' published analysis and the company disclosures referenced therein.